Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0001350
UniProt IDP22626
Primary gene name(s)HNRNPA2B1
Synonym gene name(s)HNRPA2B1
Protein nameHeterogeneous nuclear ribonucleoproteins A2/B1
Protein functionHeterogeneous nuclear ribonucleoprotein, hnRNP that associates with nascent pre-mRNAs, packaging them into hnRNP particles. The hnRNP particle arrangement on nascent hnRNA is non-random and sequence-dependent and serves to condense and stabilize the transcripts and minimize tangling and knotting. Packaging plays a role in various processes such as transcription, pre-mRNA processing, RNA nuclear export, subcellular location, mRNA translation and stability of mature mRNAs, PubMed:19099192. Forms hnRNP particles with at least 20 other different hnRNP and heterogeneous nuclear RNA in the nucleus. Involved in transport of specific mRNAs to the cytoplasm in oligodendrocytes and neurons: acts by specifically recognizing and binding the A2RE, 21 nucleotide hnRNP A2 response element or the A2RE11, derivative 11 nucleotide oligonucleotide sequence motifs present on some mRNAs, and promotes their transport to the cytoplasm, PubMed:10567417. Specifically binds single-stranded telomeric DNA sequences, protecting telomeric DNA repeat against endonuclease digestion, By similarity. Also binds other RNA molecules, such as primary miRNA, pri-miRNAs: acts as a nuclear 'reader' of the N6-methyladenosine, m6A mark by specifically recognizing and binding a subset of nuclear m6A-containing pri-miRNAs. Binding to m6A-containing pri-miRNAs promotes pri-miRNA processing by enhancing binding of DGCR8 to pri-miRNA transcripts, PubMed:26321680. Involved in miRNA sorting into exosomes following sumoylation, possibly by binding, m6A-containing pre-miRNAs, PubMed:24356509. Acts as a regulator of efficiency of mRNA splicing, possibly by binding to m6A-containing pre-mRNAs, PubMed:26321680. {ECO:0000250|UniProtKB:A7VJC2, ECO:0000269|PubMed:10567417, ECO:0000269|PubMed:24356509, ECO:0000269|PubMed:26321680, ECO:0000303|PubMed:19099192}.; FUNCTION:, Microbial infection Involved in the transport of HIV-1 genomic RNA out of the nucleus, to the microtubule organizing center, MTOC, and then from the MTOC to the cytoplasm: acts by specifically recognizing and binding the A2RE, 21 nucleotide hnRNP A2 response element sequence motifs present on HIV-1 genomic RNA, and promotes its transport. {ECO:0000269|PubMed:15294897, ECO:0000269|PubMed:17004321}.
Subcellular locationNucleus, nucleoplasm {ECO:0000269|PubMed:17289661}. Cytoplasmic granule {ECO:0000269|PubMed:17289661, ECO:0000269|PubMed:24356509}. Secreted, exosome {ECO:0000269|PubMed:24356509}. Note=Localized in cytoplasmic mRNP granules containing untranslated mRNAs, PubMed:17289661. Component of ribonucleosomes, PubMed:17289661. Not found in the nucleolus, PubMed:17289661. Found in exosomes follwong sumoylation, PubMed:24356509. {ECO:0000269|PubMed:17289661, ECO:0000269|PubMed:24356509}.;
SUBCELLULAR LOCATION: Isoform A2: Nucleus {ECO:0000269|PubMed:10772824, ECO:0000269|PubMed:17289661, ECO:0000269|PubMed:24098712}. Cytoplasm {ECO:0000269|PubMed:10772824, ECO:0000269|PubMed:17289661}. Note=Predominantly nucleoplasmic, however is also found in the cytoplasm of cells in some tissues, PubMed:17289661. {ECO:0000269|PubMed:17289661}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P22626
Gene Ontology
(Biological Process)
Complete annatation
gene expression [GO:0010467];
miRNA transport [GO:1990428];
mRNA export from nucleus [GO:0006406];
mRNA processing [GO:0006397];
mRNA splicing, via spliceosome [GO:0000398];
negative regulation of mRNA splicing, via spliceosome [GO:0048025];
negative regulation of transcription from RNA polymerase II promoter [GO:0000122];
primary miRNA processing [GO:0031053];
RNA transport [GO:0050658]
Gene Ontology
(Molecular Function)
Complete annatation
miRNA binding [GO:0035198];
mRNA 3'-UTR binding [GO:0003730];
N6-methyladenosine-containing RNA binding [GO:1990247];
nucleotide binding [GO:0000166];
poly(A RNA binding [GO:0044822];
pre-mRNA intronic binding [GO:0097157];
RNA binding [GO:0003723];
single-stranded telomeric DNA binding [GO:0043047]
Gene Ontology
(Cellular Component)
Complete annatation
catalytic step 2 spliceosome [GO:0071013];
cytoplasm [GO:0005737];
extracellular exosome [GO:0070062];
intracellular ribonucleoprotein complex [GO:0030529];
membrane [GO:0016020];
nucleoplasm [GO:0005654];
nucleus [GO:0005634];
spliceosomal complex [GO:0005681]
Protein-protein interaction109422
Phylogenetic treeP22626
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD30.9550177783764290.00417301760870170.0124817863461703
AZA vs. DISU-0.0555172286641890.8258870282682710.985177903861482
AZA vs. IL70.3184328435121370.09653289706578070.825971912953959
AZA vs. SAHA0.01232765600156590.9595688746619590.990779256780515
DISU vs. CD3-1.023591836309850.005889501402782770.0186157148554304
DISU vs. IL70.3647166195432180.1475854220917230.500122141875431
DISU vs. SAHA0.06930311458281830.8115737837071650.951302109427298
DMSO vs. AZA0.01374930691256180.934216819556491
DMSO vs. CD3-0.9494467448920570.003533938574377450.0102362593007107
DMSO vs. DISU0.06832302048093640.778970966958370.971585548411322
DMSO vs. IL70.3114270388863010.08217387678606920.536961938686603
DMSO vs. SAHA-0.009263899774820290.968556717417080.993151232958031
HIV vs. Mock in Activation0.1382221916139510.8239135109563170.999983755607037
HIV vs. Mock in Latency-0.06286697322442790.7019801407993750.999834320637052
IL7 vs. CD3-0.6292064613144130.05254983866116380.114398929725301
SAHA vs. CD3-0.9672812149396250.007340257217180790.0197743432718832
SAHA vs. IL7-0.3093869534877890.2031734268759010.436251025192972
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change -1.059523494
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.598653 0.000305467
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
1.044 0.967 0.92 0.945 0.996
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

not found

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1X4B NMR - A=1-103.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Gag-Pol complexes with 23125841
Vpr regulated by 25169827
integrase binds 20016921
Nef complexes with 23125841
Rev interacts with 22174317
Envelope surface glycoprotein gp120 complexes with 23125841
retropepsin cleaves 22944692
Vif regulated by 23255806
Pr55(Gag) complexes with 23125841
Pr55(Gag) regulated by 22187150
Envelope surface glycoprotein gp120 regulated by 22187150
Envelope surface glycoprotein gp160; precursor regulated by 22187150
Tat downregulates 23166591

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
not found